Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Digging Deeper: Covia’s Formula for Products and Progress
Tomorrow’s World Today® Podcast
33 minutes
2 months ago
Digging Deeper: Covia’s Formula for Products and Progress
Learn more about: Covia Featured on: Season 5 Episode 5 - Tomorrow's World Today Ever wonder what's inside your kitchen countertop or the sand trap that ruined your golf score? Andrew Eich, former President and CEO of Covia, pulls back the curtain on the fascinating world of industrial mineral mining, revealing how these essential materials become part of our everyday lives. With operations spanning 42 sites across North America and 2,000 employees, Covia stands as the first crucial step in c...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
